Jacob Eswarakumar, Ph.D.

Founder, CEO, and Chief Scientific Officer

Therapeutic Areas

Drug	Indication	Phase
FGFR2-related Syndromic Craniosynostosis Program	Pfeiffer, Apert, and Crouzon syndromes	Pre-clinical